TARS in the 13F filings
Tarsus Pharmaceuticals Inc · CUSIP 87650L103
- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 19 Feb 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 28
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 3 listed it in both
- Shares listed
- 5,922,952
- combined, among listed positions
- Reported value
- $485m
- combined, at the quarter end
Among the 92 comparable managers: 18 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +1,212,811.
Managers listing TARS in Q4 2025
28 of 28 holders
Largest increases and reductions, by shares
Increases
- Fidelity (FMR LLC)existing position · 647,114 shares now+625,253
- Janus Henderson Group Ltdexisting position · 1,930,325 shares now+491,326
- Invesco Ltdexisting position · 1,012,357 shares now+75,351
- T. Rowe Price Associates Incexisting position · 518,780 shares now+65,923
- ExodusPoint Capital Management LPnew position · 51,487 shares now+51,487
Reductions
- Artisan Partners LPexisting position · 436,576 shares now-121,750
- Squarepoint Ops LLCexisting position · 21,833 shares now-59,646
- Jane Street Group LLCexisting position · 20,486 shares now-40,134
- Voloridge Investment Management LLCexisting position · 23,363 shares now-35,464
- Brevan Howard Capital Management LPexisting position · 4,458 shares now-17,969
New positions and exits
New (8)
Exited (2)
- Citadel Advisors LLCwas $2.6m
- Man Group PLCwas $666k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2021 | 1 | $397k | n.a. | n.a. |
| Q3 2023 | 2 | $14m | n.a. | n.a. |
| Q4 2023 | 2 | $13m | 0 | 2 |
| Q1 2024 | 2 | $31m | 1 | 1 |
| Q2 2024 | 2 | $35m | 2 | 0 |
| Q3 2024 | 5 | $62m | 5 | 0 |
| Q4 2024 | 4 | $46m | 2 | 2 |
| Q1 2025 | 1 | $31m | 0 | 1 |
| Q2 2025 | 3 | $98m | 2 | 1 |
| Q3 2025 | 3 | $122m | 1 | 1 |
| Q4 2025 | 4 | $202m | 18 | 10 |
| Q1 2026 | 4 | $184m | 14 | 14 |
| Q2 2026 | 4 | $201m | 16 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TARS and GILD →TARS and AMGN →TARS and ARGX →Choose a stock to compare with TARS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TARS, latest filings →Back to the 13F Explorer →